Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Ziopharm Oncology Completes Enrollment of Controlled IL-12 plus Opdivo® (nivolumab) Phase 1 Combination Trial in Brain Cancer
– Enrollment completed in third cohort of dose-escalation study at leading brain cancer hospitals in US; Investigators indicate interest in expanding study – BOSTON , June 26, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) today announced completion of
View HTML
Toggle Summary Ziopharm Oncology Appoints Heidi Hagen to Board of Directors
Operations Management Leader for Immunex, Dendreon; Co-Founder and Chief Strategy Officer of Vineti BOSTON , June 17, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP), today announced Heidi Hagen , an experienced and entrepreneurial biotechnology
View HTML
Toggle Summary Ziopharm Oncology Announces FDA Clearance of IND for Sleeping Beauty TCR-T Cell Therapy Trial at NCI
– Positions Ziopharm to be first company to bring non-viral TCR-T into the clinic – – Company to host informational conference call June 12, 2019 at 8:30 am ET – BOSTON , June 11, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (“Ziopharm” or “the Company”) (Nasdaq:ZIOP) announced that the
View HTML
Toggle Summary Ziopharm Oncology Provides Positive Clinical Data for Controlled IL-12 for the Treatment of Recurrent Glioblastoma at the 2019 ASCO Annual Meeting
– Controlled IL-12 evaluated as monotherapy in an expanded number of patients confirmed rapid and safe activation of immune system  –  –Controlled IL-12 can be combined with increasing doses of a PD-1 inhibitor and immune profiling data is encouraging – BOSTON , June 02, 2019 (GLOBE NEWSWIRE) --  
View HTML
Toggle Summary Ziopharm Oncology Announces Exclusive License with National Cancer Institute to Identify and Use T-Cell Receptors Targeting Neoantigens for Cancer with Sleeping Beauty Platform
– Scope of license includes library of T-cell receptors (TCRs) against neoantigens in hotspots including mutated KRAS, p53 and EGFR for use with Sleeping Beauty platform –  – Ziopharm also obtains license to manufacturing technologies for Sleeping Beauty -modifed TCR-expressing T cells targeting
View HTML
Toggle Summary Ziopharm Oncology Presentation at the Jefferies 2019 Global Healthcare Conference to be Webcast
BOSTON , May 23, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that Laurence Cooper , M.D., Ph.D., CEO of Ziopharm, is scheduled to participate in a webcast session at the
View HTML
Toggle Summary Ziopharm Oncology Reports First Quarter 2019 Financial Results and Reaffirms Clinical Timelines
- Phase 1 Trial of Sleeping Beauty TCR-T cell therapy for patients with solid tumors to begin at NCI in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 –   - Phase 2 trial of Controlled IL-12 in combination with Regeneron’s Libtayo ® for  patients
View HTML
Toggle Summary Ziopharm Oncology to Host Conference Call to Discuss First Quarter 2019 Financial Results on May 8, 2019
BOSTON , May 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq:ZIOP) today announced that management will host a conference call and webcast on Wednesday, May 8 , at 4:30 p.m. ET to provide a corporate update and discuss financial results for the first quarter ended March 31 , 2019. 
View HTML
Toggle Summary Ziopharm Oncology Announces FDA Fast Track Designation for Ad-RTS-hIL-12 plus Veledimex for the Treatment of Recurrent Glioblastoma
BOSTON , April 01, 2019 (GLOBE NEWSWIRE) -- Ziopharm Oncology , Inc. (Nasdaq: ZIOP), a clinical stage immuno-oncology company developing next generation cell and gene therapies, today announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation for its Controlled
View HTML
Toggle Summary Ziopharm Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Phase 1 Trial of Sleeping Beauty -TCR-T cell therapy for patients with solid tumors to begin at National Cancer Institute in mid-2019 – - Third-generation Sleeping Beauty CD19-specific CAR-T U.S. trial to begin in 2H2019 –   - Eden BioCell to advance third-generation Sleeping Beauty CAR-T for
View HTML